Accuracy of coronary MR plaque imaging in patient with chronic kidney disease associated with coronary artery disease

Validation of the accuracy of coronary MR plaque imaging for disease management in patient with chronic kidney disease associated with very high-risk for coronary artery disease - ACUAMARINE-CKD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1052210075

Enrollment

524

Registered

2021-09-05

Start date

2023-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease, ischemic stroke, hypertension, peripheral arterial disease, diabetes mellit Chronic kidney disease, Coronary artery disease, Diabetic Mellitus

Interventions

Magnetic resonance coronary plaque imaging and magnetic resonance angiography

cardiac magnetic resonance, chronic kidney disease, coronary artery disease

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stage 3 or higher chronic kidney disease with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 with suspected coronary artery disease or angina pectoris

Exclusion criteria

Exclusion criteria: Patients with suspected acute coronary syndrome Patients who have had myocardial infarction within 3 months Patients with contraindication for MRI examination Patients undergoing hemodialysis or peritoneal dialysis Patients with a resting pulse rate of 80 beats per minute or higher, or patients with chronic atrial fibrillation Patients who cannot give their consent. Patients who have difficulty in understanding the contents of this study and who are judged to be inappropriate by the physician in charge.

Design outcomes

Primary

Measure	Time frame
A composite of death from coronary heart disease and all cause death, nonfatal myocardial infarction, ischemia-driven unplanned coronary intervention (percutaneous coronary intervention or coronary bypass surgery, or hospitalization for unstable angina pectoris)	—

Secondary

Measure	Time frame
1) Incidence of composite cardiovascular events after 144 weeks of research testing (long-term prognosis) 2) Cost-effectiveness analysis 3) Comparison of management status (prescription rate of secondary prevention drugs for coronary artery disease and attainment of control goals for blood pressure, lipids, and diabetes; additional imaging tests (myocardial SPECT and cardiac MRI); and PCI or coronary artery bypass) after cardiac MRI and conventional testing 4) Complication rate of coronary artery HIP in high-risk patients for primary prevention of coronary artery disease with a Suita score of 66 or higher (Plaque to Myocardium Ratio (PMR) value of 1.1 or higher, and coronary artery HIP complication rate of 1.3 or higher)	—

Measure

Time frame

1) Incidence of composite cardiovascular events after 144 weeks of research testing (long-term prognosis) 2) Cost-effectiveness analysis 3) Comparison of management status (prescription rate of secondary prevention drugs for coronary artery disease and attainment of control goals for blood pressure, lipids, and diabetes; additional imaging tests (myocardial SPECT and cardiac MRI); and PCI or coronary artery bypass) after cardiac MRI and conventional testing 4) Complication rate of coronary artery HIP in high-risk patients for primary prevention of coronary artery disease with a Suita score of 66 or higher (Plaque to Myocardium Ratio (PMR) value of 1.1 or higher, and coronary artery HIP complication rate of 1.3 or higher)

—

Contacts

Public ContactTeruo Noguchi

National Cerebral and Cardiovascular Center

tnoguchi@ncvc.go.jp+81-6-6170-1070

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026